Vertex Pharmaceuticals (VRTX) Payables (2009 - 2026)

Vertex Pharmaceuticals (VRTX) has reported Payables for 18 consecutive years, with $489.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Payables rose 9.96% year-over-year to $489.3 million; the TTM figure through Mar 2026 stood at $489.3 million (up 9.96% YoY), while the FY2025 annual figure was $461.7 million, up 11.79% from the prior year.
• Payables came in at $489.3 million for Q1 2026 at Vertex Pharmaceuticals, up from $461.7 million in the prior quarter.
• The five-year high for Payables was $489.3 million in Q1 2026, with the low at $126.9 million in Q3 2022.
• Average Payables over 5 years is $351.5 million, with a median of $364.9 million recorded in 2023.
• Across the five-year window, Payables surged 196.22% in 2023 and declined 9.67% in 2024, its largest moves.
• Year by year, Payables stood at $303.9 million in 2022, then grew by 20.07% to $364.9 million in 2023, then increased by 13.18% to $413.0 million in 2024, then advanced by 11.79% to $461.7 million in 2025, then rose by 5.98% to $489.3 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $489.3 million, $461.7 million, and $420.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.